Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program

This study compared initiation of insulin and other antihyperglycaemic agents (AHAs) with canagliflozin versus placebo for participants with type 2 diabetes and a history/high risk of cardiovascular disease in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. After 1 year, fewer participants treated with canagliflozin versus placebo initiated any AHA (7% vs. 16%), insulin (3% vs. 9%) or any non‐insulin AHA (5% vs. 12%) (P < .001 for all); overall AHA initiation rates increased over time but were consistently lower with canagliflozin compared with placebo. During the study, the likelihood of initiating insulin was 2.7 times lower for participants treated with canagliflozin compared with placebo (hazard ratio, 0.37; 95% CI: 0.31, 0.43; P < .001). The time difference between 10% of patients in the canagliflozin and placebo groups being initiated on insulin from the beginning of the trial was about 2 years. Time to initiation of other AHAs, including metformin, dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists and sulphonylureas, was also delayed for canagliflozin versus placebo (P < .001 for each). Compared with placebo, canagliflozin delayed the need for initiation of other AHAs and delayed time to insulin therapy, an outcome that is important to many people with diabetes.

• Publication year

  2020

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2020-04-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dom.14143PMID 32691499PMCID 7693248
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial

  2021cited by this paper
• 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME

  2020cited by this paper
• Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program

  2020cited by this paper
• Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.

  2019cited by this paper
• Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?

  2019cited by this paper
• Erratum. Insulin Access and Affordability Working Group: Conclusions and Recommendations. Diabetes Care 2018;41;1299–1311

  2018cited by this paper
• Insulin Access and Affordability Working Group: Conclusions and Recommendations

  2018cited by this paper
• Perceptions of insulin use in type 2 diabetes in primary care: a thematic synthesis

  2018cited by this paper
• Trends in comorbidity burden and treatment patterns in type 2 diabetes: Longitudinal data from a US cohort from 2006 to 2014.

  2018cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials

  2017cited by this paper
• Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial

  2017cited by this paper
• On confidence intervals for the hazard ratio in randomized clinical trials

  2016cited by this paper
• Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus

  2015cited by this paper
• Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

  2013cited by this paper
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

  1977cited by this paper

• Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japan

  2025cites this paper
• Efficacy and Safety of Canagliflozin in STEMI Patients with Type 2 Diabetes after PCI: A Retrospective Study

  2024cites this paper
• Real-world data of glycemic control in a suburban population in northern india during the COVID-19 pandemic

  2023cites this paper
• "Insulin independence with SGLT2 inhibitor use in Type 2 Diabetes".

  2023cites this paper
• Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV

  2023cites this paper
• Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial

  2021cites this paper
• Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program

  2020cites this paper